{"filings":[{"id":2547797,"accession_number":"0001070081-26-000019","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-08-28T20:06:46+00:00","items":["1.01"],"status":"ready","headline":"PTC Therapeutics to acquire ST-920 gene therapy for Fabry disease from Sangamo for $111M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $111M plus up to $100M milestones: $80M on FDA accelerated approval, $20M on full approval of ST-920 BLA.","ST-920 is a one-time AAV gene therapy candidate for Fabry disease, acquired from Sangamo in bankruptcy auction.","Closing subject to Bankruptcy Court approval (hearing Sept 10, 2026) and HSR waiting period; deadline Oct 15, 2026.","PTC was selected as winning bidder in Sangamo's Chapter 11 case; agreement includes customary reps/warranties, no indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2226045,"accession_number":"0001104659-26-095424","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-08-13T11:00:19+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PTC wins bankruptcy auction for Sangamo's Fabry gene therapy ST-920; $111M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal: $111M upfront plus up to $100M milestones ($80M on accelerated approval, $20M on traditional FDA approval).","ST-920 is a one-time AAV gene therapy; BLA submission for accelerated approval expected Q4 2026.","Phase 1/2 STAAR data showed positive eGFR slope at 52 weeks; durability up to 4.5 years in earliest patient.","Close expected late Q3/early Q4 2026, subject to bankruptcy court approval, antitrust review, and customary conditions.","PTC expects no impact on 2026 cash flow break-even; leverages existing rare disease commercial infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1967720,"accession_number":"0001070081-26-000016","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-07-30T20:05:37+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics Q2 net income $83.5M, raises FY product revenue guidance to $850-950M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $361M (product $239M) includes $50M Novartis milestone; net income $83.5M vs net loss $64.8M YoY.","FY 2026 product revenue guidance raised to $850-950M (from $750-850M); total revenue guidance raised to $1.18-1.28B.","Sephience Q2 revenue $151M (+21% QoQ); 1,647 patients on therapy; Translarna $42.2M, Emflaza $24.6M, Evrysdi royalty $71.1M.","Issued $550M senior convertible notes due 2031 at 0% coupon, 40% conversion premium; repurchased majority of 1.5% notes due 2026. Cash $2.23B.","Pipeline: PTC303 (MSH3) targeting Huntington's, clinic entry 2027; PTC612 (NLRP3) Phase 1 initiated; vatiquinone PROVE-FA study Q3 2026; votoplam PIVOT-HD 24-month results showed 52% disease slowing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1138679,"accession_number":"0001104659-26-075731","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-06-18T20:14:58+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"PTC Therapeutics closes $550M zero-coupon convertible notes offering, repurchases $222M of existing notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $550M aggregate principal of 0.0% Convertible Senior Notes due 2031, initial conversion price ~$107.48/share.","Net proceeds approximately $535.5M after discounts and estimated offering expenses.","Using ~$328.8M to repurchase $222M principal of existing 1.50% Convertible Senior Notes due 2026; $55.5M remains outstanding.","Notes are general unsecured senior obligations; company may redeem after June 20, 2029 if stock price >=130% of conversion price.","Initial purchasers exercised in full their option to purchase an additional $50M of notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1065760,"accession_number":"0001104659-26-074292","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-06-16T11:00:33+00:00","items":["8.01","9.01"],"status":"ready","headline":"PTC Therapeutics prices $500M 0% convertible notes due 2031 to refinance 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced $500M aggregate principal of 0% Convertible Senior Notes due 2031; initial purchasers have option for additional $50M.","Conversion price set at $107.48 per share, a 40% premium over June 15 closing price of $76.77.","Approximately $328.8M of net proceeds will be used to repurchase $222M of outstanding 1.5% convertible notes due 2026.","Closing expected on June 18, 2026; notes are senior unsecured obligations and mature June 15, 2031.","Remaining net proceeds will be used for general corporate purposes, including potential additional repurchases of 2026 notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":947837,"accession_number":"0001104659-26-071916","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-06-09T21:15:22+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Alethia Young resigns from PTC board, stays as consultant at $4,167/month","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alethia Young resigned from the Board effective June 8, 2026; no disagreement cited.","She entered a consulting agreement through June 8, 2027 for monthly fee of $4,166.67.","Outstanding stock options and RSUs will continue to vest during consulting term.","Exercisability of options extends to three years after termination (max 10 years from grant)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":890636,"accession_number":"0001104659-26-071040","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-06-05T21:15:21+00:00","items":["5.07"],"status":"ready","headline":"PTC Therapeutics shareholders elect four Class I directors and ratify Ernst & Young","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jessica Chutter, Matthew Klein, Stephanie Okey, and Jerome Zeldis elected Class I directors with >83% of votes cast.","Ernst & Young LLP ratified as independent auditor for FY 2026 with 76.2M for, 0.4M against.","Say-on-pay advisory proposal approved with 71.2M for, 1.5M against, 3.9M broker non-votes.","Annual meeting held June 2, 2026; 82.9M shares outstanding as of April 10, 2026 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91075,"accession_number":"0001070081-26-000011","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics Q1 revenue $273M, raises FY product revenue guidance to $750-850M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 total revenue $273M; product revenue $226M, up 47% YoY.","Net loss $2.8M vs net income $866.6M in Q1 2025 (prior year included non-recurring gain).","Sephience revenue $124.6M, up 36% QoQ; 1,244 patients on commercial therapy globally.","FY 2026 product revenue guidance raised to $750-850M; total revenue expected $1.08-1.18B.","Positive votoplam PIVOT-HD data; $50M milestone from Novartis triggered in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":272551000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91074,"accession_number":"0001070081-26-000006","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PTC Therapeutics reports positive PIVOT-HD extension data: 52% slowing of HD progression at 10 mg votoplam","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stage 2 HD participants showed 52% (10 mg) and 28% (5 mg) slowing on cUHDRS vs natural history at 24 months.","Mean NfL levels remained below baseline at 24 months for both doses, contrasting with natural history increases.","Safety data at Month 24 consistent with prior favorable safety profile; no treatment-related NfL increases.","Novartis has initiated global Phase 3 INVEST-HD study of votoplam (10 mg vs placebo, n≈770, primary endpoint cUHDRS at 36 months)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100980,"accession_number":"0001104659-26-034207","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics appoints biotech banking veteran Jessica Chutter to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jessica Chutter appointed to board effective March 24, 2026, as Class I director.","Chutter spent 40+ years at Morgan Stanley, most recently as Managing Director and Chair of Biotech Investment Banking.","She was involved in ~$80B in capital raising and ~$85B in strategic transactions at Morgan Stanley.","Initial director equity grant: 3,475 stock options (36-month monthly vest) and 4,000 RSUs (3-year annual vest).","Also receives pro-rated annual grant: 2,896 stock options and 3,333 RSUs; eligible for future grants per board policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100979,"accession_number":"0001104659-26-017546","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics reports FY2025 product/royalty rev $831M, beats guidance; Sephience Q4 rev $92M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 product/royalty revenue $831M, exceeding guidance; total revenue $1.73B (includes $998M Novartis collaboration).","Sephience launch strong: Q4 rev $92M ($81M US), 946 patients on therapy; full-year rev $111M.","Net income $682.6M for FY2025 vs net loss $363.3M in FY2024; cash $1.95B as of Dec 31.","Sold Evrysdi royalty to Royalty Pharma for $240M upfront + up to $60M milestones; retains $150M Roche milestone.","2026 guidance: product rev $700-800M (19-36% growth); Phase 3 HD trial INVEST-HD to start 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":7.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":1730655000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100978,"accession_number":"0001104659-26-014414","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PTC Therapeutics withdraws Translarna NDA resubmission after FDA cites insufficient efficacy data","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Withdrew NDA resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy.","FDA feedback indicated data unlikely to meet substantial evidence of effectiveness threshold.","CEO Matthew Klein expressed disappointment after more than two decades of development efforts.","No path to FDA approval for Translarna in the U.S. at this time.","PTC Therapeutics (PTCT) shares potential negative impact from this regulatory setback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100977,"accession_number":"0001104659-26-002799","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics: 2025 preliminary revenue ~$823M, Sephience $112M; 2026 guidance $700-800M product revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary 2025 total product & royalty revenue ~$823.4M, exceeding prior guidance; product revenue ~$587.8M.","Sephience (sepiapterin) net revenue $112.1M since launch, Q4 alone $92.5M; 946 patients on commercial therapy as of Dec 31.","Closed sale of remaining Evrysdi royalty to Royalty Pharma for $240M upfront plus up to $60M milestones; retains $150M milestone.","2026 guidance: product revenue $700-800M (19-36% YoY growth); GAAP R&D/SG&A $775-815M, non-GAAP $680-720M.","End-of-Phase 2 meeting for votoplam HD program; Phase 3 trial to start H1 2026; FDA open to Accelerated Approval."],"consensus_eps_estimate":null,"consensus_eps_actual":7.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":1730655000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117308,"accession_number":"0001104659-25-124837","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"PTC Therapeutics sells remaining Evrysdi royalty stake to Royalty Pharma for $240M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold remaining 9.5111%/16.6666% royalty interest in Evrysdi worldwide net sales for $240M upfront cash.","Up to three additional $20M payments contingent on Royalty Pharma receiving >$347M (2027), $363M (2028), $379M (2029) in royalty payments.","After closing, Royalty Pharma owns 100% of the Evrysdi royalty; PTC retains no interest.","Transaction effective December 29, 2025, under Amendment No. 2 to existing royalty purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117307,"accession_number":"0001070081-25-000026","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics Q3 net income $15.9M, Sephience launch revenue $19.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $211.0M vs $196.8M YoY; net income $15.9M vs loss of $106.7M.","Sephience launch: $19.6M revenue (US $14.4M, ex-US $5.2M), 521 start forms from 141 prescribers, 341 patients on therapy.","DMD franchise revenue $85.9M (Translarna $50.7M, Emflaza $35.2M); Evrysdi royalties $70.8M.","Full-year 2025 revenue guidance narrowed to $750-$800M; GAAP R&D/SG&A $805-$835M.","Cash and marketable securities $1,687.8M as of Sep 30, 2025 (up from $1,139.7M at Dec 31, 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":9.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":1565978000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133746,"accession_number":"0001558370-25-011658","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA denies approval of PTC Therapeutics' vatiquinone NDA for Friedreich's ataxia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL states substantial evidence of efficacy not demonstrated; additional well-controlled study needed for resubmission.","PTC plans to meet with FDA to discuss potential steps to address CRL issues.","Vatiquinone was proposed for children and adults with Friedreich's ataxia.","CEO Matthew B. Klein expressed disappointment but believes data support safe, effective therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133745,"accession_number":"0001558370-25-010786","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"PTC Therapeutics pays ~$225M upfront to cancel Censa sepiapterin royalty obligations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront cash payment of ~$225M to former Censa securityholders eliminates 8-12% annual net sales royalties.","Original milestones: 8% on sales ≤$250M, 10% on $250M-$500M, 12% on >$500M.","Additional Milestone Payments up to $100M each (total $500M) based on cumulative net sales thresholds (e.g., $3B, $5B, $7B, $9B, $11B).","Participation was ~90% of former Censa securityholders; remaining may join and receive pro rata consideration.","Sepiapterin is the product; other merger obligations remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133744,"accession_number":"0001558370-25-010770","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics Q2 2025: Sephience approved in EU and US; total revenue $179M; net loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sephience (sepiapterin) received EC and FDA approval with broad label for PKU across all ages and subtypes; global launch initiated.","Q2 total revenue $178.9M (vs $186.7M Q2 2024); DMD franchise $96M: Translarna $59.5M, Emflaza $36.4M.","Net loss improved to $64.8M from $99.2M; cash & securities $1.99B (up from $1.14B at Dec 31, 2024).","Entered agreement to buy out Censa sales milestone obligation for $225M upfront plus future milestones.","FY2025 revenue guidance $650-800M; vatiquinone PDUFA date Aug 19, 2025; positive Phase 2 HD results for votoplam."],"consensus_eps_estimate":null,"consensus_eps_actual":9.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":1354971000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133743,"accession_number":"0001558370-25-009663","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PTC Therapeutics receives FDA approval for Sephience (sepiapterin) to treat PKU in patients 1 month and older","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Sephience for hyperphenylalaninemia in adult/pediatric patients ≥1 month with sepiapterin-responsive PKU.","Approval based on Phase 3 APHENITY trial and long-term extension data showing significant efficacy and safety.","Broad labeling includes all disease subtypes; PTC CEO states Sephience could become standard of care.","SEPHIENCE recently received EU marketing authorization; reviews ongoing in Japan, Brazil and other countries.","PTC to host conference call July 28 at 5pm ET to discuss approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150462,"accession_number":"0001558370-25-008694","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PTC Therapeutics reports results of 2025 annual meeting; all three proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Allan Jacobson (60,386,986 for), David Southwell (59,200,375), Alethia Young (54,894,657) as Class III directors to 2028 term.","Ratified Ernst & Young as independent auditor for FY 2025: 67,259,475 for, 195,233 against, 21,362 abstained.","Approved non-binding advisory vote on executive compensation: 60,479,157 for, 1,979,310 against, 44,711 abstained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150461,"accession_number":"0001070081-25-000018","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics Q1 net income $866.6M on Novartis deal; guides FY revenue $650-800M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $866.6M vs loss $91.6M YoY, driven by $986.2M upfront from Novartis PTC518 license deal.","Total net product & royalty revenue $189.9M; DMD franchise (Translarna+Emflaza) $134M, down YoY.","Cash, equivalents & marketable securities $2.027B as of March 31, 2025, up from $1.14B at Dec 31, 2024.","Positive CHMP opinion for Sephience (sepiapterin) in PKU; NDA under FDA review with PDUFA July 29, 2025.","PTC518 Phase 2 PIVOT-HD met primary endpoint of dose-dependent blood HTT lowering; plans to discuss accelerated approval."],"consensus_eps_estimate":null,"consensus_eps_actual":10.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":1176096000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150460,"accession_number":"0001070081-25-000014","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PTC518 Phase 2 PIVOT-HD meets primary endpoint with dose-dependent HTT lowering at Week 12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: dose-dependent blood HTT protein reduction (p<0.0001) at Week 12.","5mg dose lowered HTT 23% in Stage 2/3; 10mg lowered 39% (Stage 2) and 36% (Stage 3).","Favorable dose-dependent trends on cUHDRS, TFC, SDMT in Stage 2 patients at 12 and 24 months.","No treatment-related SAEs or NfL spikes; safety and tolerability profile favorable.","At Month 24, dose-dependent NfL lowering: -8.9% (5mg, p=0.12) and -14% (10mg, p=0.03) vs natural history."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169434,"accession_number":"0001104659-25-029124","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"European Commission refuses renewal of Translarna (ataluren) marketing authorization in EU","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EC adopted CHMP negative opinion; renewal of conditional MA for nonsense mutation DMD denied.","Drug effectively removed from European Economic Area; authorization ends.","EC indicated EU member states may allow continued use under Articles 117(3) and 5(1) of Directive 2001/83.","PTC CEO expresses disappointment; plans to work country-by-country to maintain commercial access.","Decision based on CHMP conclusion that efficacy was not established and benefit-risk not confirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169433,"accession_number":"0001070081-25-000011","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics reports FY2024 revenue $807M above guidance; cash >$2B after Novartis deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenue $806.8M, exceeding guidance; net loss $363.3M vs $626.6M prior year.","Cash and marketable securities $1.14B at Dec 31, 2024; >$2B after Jan 2025 Novartis PTC518 deal.","Four NDAs accepted by FDA in 2024; sepiapterin PDUFA July 29, 2025, vatiquinone priority review Aug 19, 2025.","FY2025 revenue guidance $600-800M; GAAP R&D+SG&A $805-835M; cash supports commercial and R&D plans.","DMD franchise revenue $144M in Q4; Translarna $93.7M, Emflaza $50.5M; Evrysdi royalties $203.9M in FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":806780000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169432,"accession_number":"0001070081-25-000007","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics announces preliminary 2024 revenue of $814M, exceeding guidance, and 2025 financial outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary 2024 total revenue ~$814M, net product revenue ~$601M, and Evrysdi royalties ~$211M.","Four FDA approval applications submitted in 2024, including sepiapterin for PKU with FDA action date July 29, 2025 and CHMP opinion expected Q2 2025.","License and collaboration agreement with Novartis for PTC518 (Huntington's disease) closed, with $1B upfront and up to $1.9B milestones.","2025 revenue guidance $600M-$800M; GAAP R&D and SG&A expense $805M-$835M; non-GAAP $730M-$760M.","PIVOT-HD Phase 2 data readout expected Q2 2025; cash balance ~$1.1B plus additional $1B from Novartis upfront."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":806780000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169431,"accession_number":"0001070081-25-000004","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"PTC Therapeutics cuts leased space in half, reduces base rent by $57.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Surrendered one of two buildings; premises reduced from 360k to 180k sq ft.","Aggregate base rent reduced by $57.7M; continues paying full rent through Dec 2027 then lower amount.","Landlord improvement allowance cut from $36.1M to $23.9M.","Letter of credit increased to $10M from $8.1M; could drop to $5M after Jul 2027 and $2.5M after Dec 2028.","Amendment effective Dec 31, 2024; related to Warren, NJ facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186489,"accession_number":"0001070081-24-000029","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics signs $1B upfront license deal with Novartis for PTC518 HD program","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["PTC receives $1.0B upfront; eligible for up to $1.9B in development, regulatory and sales milestones.","PTC will receive 40% share of U.S. profits/losses and tiered double-digit royalties on ex-U.S. sales.","Novartis will assume global development, manufacturing and commercialization after placebo-controlled portion of PIVOT-HD trial.","Transaction expected to close in Q1 2025, subject to regulatory clearance and customary conditions.","PTC intends to use proceeds to expand splicing platform and support commercial/development portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186488,"accession_number":"0001070081-24-000026","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics sells Rare Pediatric Disease PRV for $150 million cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale price of $150 million payable in cash upon closing to an affiliate of a large pharmaceutical company.","PRV was awarded on November 13, 2024 with FDA approval of KEBILIDI (eladocagene exuparvovec-tneq) for AADC deficiency.","Transaction subject to customary closing conditions including expiration of HSR Act waiting period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186487,"accession_number":"0001070081-24-000021","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics Q3 revenue $196.8M, raises FY2024 guidance to $750-800M, multiple FDA submissions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $196.8M (vs $196.6M YoY); DMD franchise $124M (Translarna $72M, Emflaza $52M).","Net loss narrowed to $106.7M from $133M; cash & securities $1.01B.","FY2024 revenue guidance raised to $750-800M; GAAP R&D+SG&A $740-835M.","FDA accepted sepiapterin NDA (PKU) with action date July 29, 2025; AADC gene therapy BLA action Nov 13, 2024.","Plans to submit vatiquinone NDA for Friedreich ataxia in Dec 2024; fast track for PTC518 Huntington's."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":593608000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186486,"accession_number":"0001558370-24-013387","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CHMP maintains negative opinion on PTC's Translarna renewal; EC decision awaited in ~67 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP upheld negative opinion on renewal of conditional marketing authorization for Translarna (ataluren) in nmDMD after re-examination.","European Commission expected to decide on opinion adoption in approximately 67 days; Translarna remains authorized pending EC review.","CEO cites totality of evidence from three placebo-controlled trials and STRIDE registry as supportive of continued authorization.","CHMP based decision on primary analysis subpopulation of Study 041; PTC will provide all possible evidence to EC for continued authorization.","Translarna currently authorized in Europe; PTC continues to ensure availability for nmDMD patients during review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203071,"accession_number":"0001070081-24-000015","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics Q2 revenue $187M; net loss narrows to $99M; NDAs submitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $186.7M vs $213.8M YoY; DMD franchise $118M (Translarna $70M, Emflaza $47M).","Net loss $99.2M improved from $198.9M loss; cash $1.09B after $250M Royalty Pharma put option.","Submitted NDA for sepiapterin (PKU) and resubmitted NDA for Translarna (nmDMD) to FDA in July 2024.","Full-year 2024 revenue guidance $700M-$750M; GAAP R&D+SG&A $740M-$835M.","BLA for AADC deficiency gene therapy accepted with priority review; PDUFA date Nov 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":396822000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219354,"accession_number":"0001070081-24-000010","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CHMP issues negative opinion on Translarna renewal; PTC plans re-examination","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP issued negative opinion on renewal of conditional marketing authorization for Translarna (ataluren) for nmDMD.","Negative opinion follows EC request for re-review; PTC will request re-examination per EMA guidelines.","Marketing authorization remains in effect; Translarna expected on market through end of 2024 even if opinion upheld.","CEO Klein: 'STRIDE real-world evidence should not be ignored'; expert panel agreed evidence shows significant efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219353,"accession_number":"0001558370-24-009313","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["1.01","5.07","7.01","9.01"],"status":"ready","headline":"PTC518 Ph2 PIVOT-HD shows mHTT lowering and clinical trends; FDA lifts partial clinical hold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PTC518 lowered mHTT in blood by 22% (5mg) and 43% (10mg) at Month 12; similar CSF levels.","Total Motor Score worsening: 2.0 (5mg), 1.3 (10mg) vs 4.9 for placebo, suggesting slowed progression.","FDA lifted partial clinical hold on PTC518 program based on PIVOT-HD interim data.","Company received $250M from Royalty Pharma for first tranche of Evrysdi royalty sale under amended agreement.","Hopewell lease amended to significantly reduce space and rent; lease no longer considered material."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219352,"accession_number":"0001558370-24-008446","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"EC rejects CHMP negative opinion on Translarna; returns for re-evaluation; 2024 guidance paused","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EC decided not to adopt CHMP's negative opinion for Translarna annual renewal; returns to CHMP for re-evaluation.","Translarna remains authorized and available in Europe; EC asks CHMP to consider real-world evidence.","PTC pauses 2024 total revenue guidance due to uncertainty from continued Translarna authorization upside."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219351,"accession_number":"0001558370-24-005767","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics Q1 total revenue $210M, net loss narrows to $91.6M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $210M (down ~5% YoY); DMD franchise $161M (Translarna $104M, Emflaza $57M).","GAAP net loss $91.6M, improved from $139M loss in Q1 2023; cash $884.8M.","Submitted MAA for sepiapterin (PKU) and BLA for Upstaza (AADC deficiency) in March 2024.","Plans to resubmit Translarna NDA mid-2024; PIVOT-HD (PTC518) interim data in Q2 2024.","Reaffirmed FY2024 total revenue guidance $600-680M; GAAP R&D/SG&A $740-835M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":210118000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239181,"accession_number":"0001558370-24-002189","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics 2023 revenue up 34% to $938M; guides 2024 revenue $600-680M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $937.8M (+34% YoY); net loss $626.6M vs $559.0M in 2022.","DMD franchise: Translarna $356M, Emflaza $255M; Evrysdi royalty + milestone $268.9M.","Cash and securities $876.7M vs $410.7M a year ago; debt extinguishment loss $137.6M.","Pipeline: sepiapterin MAA submission in Mar 2024, NDA by Q3 2024; vatiquinone NDA expected late 2024.","2024 guidance: total revenue $600-680M (down from $938M); GAAP R&D+SG&A $740-835M."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":937822000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239180,"accession_number":"0001070081-24-000006","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PTC Therapeutics' Translarna faces withdrawal in Europe after CHMP negative opinion on renewal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP issued negative opinion on renewal of conditional marketing authorization for Translarna (ataluren) after re-examination procedure.","Negative opinion applies to Translarna for nonsense mutation Duchenne Muscular Dystrophy (nmDMD).","European Commission to adopt the opinion within 67 days, resulting in withdrawal of Translarna in Europe.","CEO Matthew B. Klein expressed disappointment, stating decision is against patient community and expert physicians."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239179,"accession_number":"0001070081-24-000003","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC reports prelim 2023 revenue $946M (+35% YoY); guides 2024 rev $600-850M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Unaudited 2023 total revenue $946M (+35% YoY); net product revenue $661M (+23% YoY).","DMD franchise: Translarna $355M, Emflaza $255M; Evrysdi royalty/collab revenue $278M.","2024 revenue guidance $600-850M (decline); GAAP R&D+SG&A $740-835M; non-GAAP $660-755M.","Sepiapterin MAA in EU Q1, NDA in US by Q3; PTC518 HD interim data Q2.","CHMP opinion on Translarna re-examination late Jan 2024; $1B Royalty Pharma deal closed."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":937822000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256694,"accession_number":"0001070081-23-000063","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics Q3 total revenues $196.6M (-9% YoY), net loss $133M; updates pipeline timelines","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["DMD franchise revenue $136M in Q3; full-year 2023 DMD guidance raised to $565-595M.","Translarna net revenue $69M; CHMP re-examination expected Jan 2024; FDA type C meeting in Q4 2023.","Sepiapterin NDA submission for PKU delayed to no later than Q3 2024; MAA to EMA in H1 2024.","PTC518 HD trial enrollment ongoing; FDA requires 6-month safety data for US dosing.","Total 2023 revenue guidance $940M-$1.0B; GAAP R&D+SG&A expenses $915-965M."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":630766000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256693,"accession_number":"0001070081-23-000059","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"PTC Therapeutics terminates $302.1M credit agreement, pays $82.1M in prepayment premiums","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Terminated Credit Agreement dated Oct 27, 2022; repaid $302.1M principal plus accrued interest.","Paid additional $82.1M in prepayment premiums, expenses, and other exit fees.","All liens and security interests securing loans under the Credit Agreement were released."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256692,"accession_number":"0001070081-23-000056","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"PTC Therapeutics monetizes Evrysdi royalties for up to $1.5B, pays off Blackstone debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PTC receives $1.0B upfront for ~38% additional Evrysdi royalty; total ~81% sold to Royalty Pharma.","PTC can sell remaining royalty for up to $500M via puts through Dec 2025; Royalty Pharma may call up to $250M.","Proceeds to retire all Blackstone debt; Credit Agreement from Oct 2022 terminated.","PTC retains all economics on up to $250M in commercial sales milestones for Evrysdi."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274065,"accession_number":"0001070081-23-000053","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics cuts 25% workforce, targets 20% OPEX reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~25% primarily in US early-stage research and gene therapy manufacturing.","Estimated severance and benefit costs of ~$21M, substantially all cash expenditures.","Annualized operating expenses expected to drop ~20% vs 2023 OPEX guidance.","Plans to submit re-examination request for CHMP negative opinion on Translarna.","Reduction substantially complete by January 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274064,"accession_number":"0001104659-23-103032","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PTC Therapeutics removes redactions from $300M credit agreement, disclosing Events of Default terms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed unredacted Credit Agreement dated Oct 27, 2022; initial term loan facility of $300M and delayed draw up to $150M.","Company no longer seeks confidential treatment for Section 8.01 (Events of Default) and other provisions.","Credit agreement also contemplates up to $500M in incremental investments subject to lender consent.","Lenders include Blackstone-related entities; interest rate is Adjusted Term SOFR + 7.25%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274063,"accession_number":"0001558370-23-015770","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-09-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CHMP issues negative opinion on Translarna full authorization; PTC to seek re-examination","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP gave negative opinion on converting Translarna's conditional MA to full MA for nmDMD.","Negative opinion also applies to renewal of existing conditional authorization.","PTC will submit re-examination request; expected CHMP opinion in Jan 2024, EC ratification within 67 days.","Translarna stays on market for nmDMD patients during re-examination process.","PTC cites favorable safety profile & efficacy data from 3 placebo-controlled trials and STRIDE registry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274062,"accession_number":"0001070081-23-000048","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PTC Therapeutics Q2 revenue $214M (+29% YoY); raises full-year guidance to $940M-$1.0B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $213.8M vs $165.5M Q2 2022; DMD franchise $162M (+21%).","Translarna net revenue $96.5M; Emflaza $65.7M; Evrysdi royalties $36.9M.","Sepiapterin APHENITY trial met primary endpoint; NDA filing planned Q4 2023.","GAAP net loss $198.9M; cash $337.9M; gene therapy discontinues caused $88M non-cash charge.","Full-year 2023 total revenue guidance raised to $940M-$1.0B; DMD product revenue guidance $545-$575M."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":434190000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274061,"accession_number":"0001070081-23-000043","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PTC Therapeutics provides regulatory timeline updates for sepiapterin, Upstaza, Translarna","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Expects to submit NDA to FDA for sepiapterin (PKU) in Q4 2023.","Expects to submit BLA to FDA for Upstaza (AADC deficiency) in Q3 2023.","Expects CHMP opinion in Q3 2023 for Translarna (nmDMD) conversion to standard EU authorization.","Preparing Type C FDA meetings for Translarna NDA resubmission and vatiquinone NDA for Friedreich ataxia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274060,"accession_number":"0001070081-23-000040","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"PTC Therapeutics appoints Pierre Gravier as CFO effective July 13, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pierre Gravier, age 38, appointed CFO; previously managing director at Perella Weinberg Partners.","Annual base salary of $525,000; target annual bonus of 45% of base salary.","Received inducement equity: 26,000 RSUs (4-year vest) and option for 65,000 shares (4-year vest).","Severance: 15 months base salary plus health benefits if terminated without cause or for good reason.","Employment agreement includes perpetual confidentiality, 15-month non-compete/non-solicit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291228,"accession_number":"0001070081-23-000036","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PTC Therapeutics reports positive interim Phase 2 data for PTC518 in Huntington's disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim data from PIVOT-HD Phase 2 study shows dose-dependent lowering of HTT protein in blood, with mean 30% reduction at 10mg dose.","PTC518 treatment well tolerated; no treatment-related serious adverse events or dose-limiting toxicities reported.","No CSF NfL treatment-related spikes; trend towards lowering of CSF NfL levels after 12 weeks.","Conference call held June 21, 2023 at 8:00 AM EDT to discuss data; slides furnished as Exhibit 99.2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291227,"accession_number":"0001070081-23-000033","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"PTC Therapeutics annual meeting votes: all director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class I directors: William F. Bell, Jr., Matthew B. Klein, Stephanie S. Okey, Jerome B. Zeldis; each received >58M votes for.","Ratified Ernst & Young as independent auditor for FY2023: 69.4M for, 0.4M against, 13.6K abstain.","Advisory say-on-pay proposal approved: 65.3M for, 1.5M against, 21.7K abstain, 3.0M broker non-votes.","74.0M shares outstanding as of record date April 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291226,"accession_number":"0001104659-23-063688","cik":1070081,"company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["2.05","5.02","7.01","8.01","9.01"],"status":"ready","headline":"PTC discontinues early gene therapy programs, CFO terminated, vatiquinone Phase 3 misses primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinues preclinical/early gene therapy programs; workforce reduction of ~8%; expects 15% OPEX savings in 2023; severance costs ~$7M.","CFO Emily Hill terminated effective immediately; employment ends Aug 20, 2023; eligible for severance without cause.","Phase 3 MOVE-FA trial of vatiquinone in Friedreich ataxia misses primary endpoint (mFARS change, p=0.14). Subscales and completers analysis show signals.","Company to discuss potential registration path with regulators despite missing primary endpoint; vatiquinone well tolerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5861200015.539098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-05-23T23:59:59+00:00|291226"}